Inspire Medical Investors Face Jan. 5 Deadline in Securities Class Action Over Inspire V Rollout

Plaintiffs allege executives overstated Inspire V's readiness, precipitating a guidance cut that coincided with a steep share drop.

Overview

The case is pending in the U.S. District Court for the District of Minnesota as City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., No. 0:25-cv-04247.
The alleged class period covers purchases of Inspire common stock from August 6, 2024 through August 4, 2025.
Complaints cite operational problems including delayed Medicare claims software updates effective July 1, 2025, incomplete training and onboarding at treatment centers, and excess inventory of the prior Inspire IV device.
On August 4, 2025 the company disclosed an elongated Inspire V rollout and cut 2025 EPS guidance by more than 80%, and the stock fell about $42.04 or roughly 32% by August 5.
Multiple firms, including Bleichmar Fonti & Auld, Hagens Berman, Rosen Law Firm, and Levi & Korsinsky, are soliciting investors for Section 10(b) and 20(a) claims, and no class has been certified.